Physician profile
John B Johnson
NPI 1902553647
$2,442.86
in general payments reported to CMS, 2019-2025
23 companies · $602 in 2025
The $602 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $443 · 2023: $649 · 2024: $748 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.44 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $634.42 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $373.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $257.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.75 | 2022-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $175.86 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $175.73 | 2023-2025 | |
| Glaxosmithkline, LLC. | $69.24 | 2023 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $68.90 | 2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $55.95 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.73 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.61 | 2024-2025 | |
| Boston Scientific Corporation | $48.84 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $45.20 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Organon LLC | $43.62 | 2022 | |
| Exact Sciences Corporation | $39.51 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $35.11 | 2025 | |
| Viiv Healthcare Company | $24.38 | 2025 | Dovato |
| Astellas Pharma US INC | $18.88 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2025 | Cobenfy |
| Cranial Technologies, INC | $17.49 | 2024 | Doc Band |
| Baxter Healthcare | $16.56 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Sumitomo Pharma America, INC. | $16.45 | 2023 | Gemtesa |
| Amgen INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.